Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.

Virology, published by Academic Press Inc. Elsevier Science, is a prominent journal dedicated to advancing the knowledge and understanding of viral biology and pathogenesis since its inception in 1955. With a distinguished impact factor and recognized as a Q2 journal in the field of Virology for 2023, it ranks 38 out of 80 in the Scopus database for Immunology and Microbiology, placing it in the 53rd percentile among similar publications. This esteemed journal provides a platform for groundbreaking research, critical reviews, and comprehensive studies that contribute to our global understanding of viruses and their impact on health and disease. Although currently not an open-access journal, it remains accessible to a wide audience of researchers, professionals, and students who are keen to explore the latest advancements in virological research. The journal's scope encompasses a diverse range of topics, ensuring that it serves as an essential resource for anyone engaged in virology and related biomedical fields.

Future Virology, published by Future Medicine Ltd, is an essential journal dedicated to advancing the understanding of virology in the contemporary scientific landscape. With an ISSN of 1746-0794 and an E-ISSN of 1746-0808, this journal serves as a platform for researchers and practitioners in the field to publish high-quality, peer-reviewed articles that explore novel discoveries, innovative therapeutic strategies, and the implications of viral research on global health. Operating from the United Kingdom and maintaining a commitment to rigorous scientific inquiry, Future Virology is categorized in the Q4 Quartile for Virology according to the latest Scopus rankings, with a position of Rank #48/80 and a percentile of 40th in the Virology category. Although it currently does not offer open access, the journal strives to disseminate critical insights that benefit a wide range of professionals, researchers, and students engaged in virology and related fields. By bridging the gap between basic research and practical applications, Future Virology plays a crucial role in fostering innovation and collaboration in the ever-evolving virology landscape.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.

JOURNAL OF MEDICAL VIROLOGY is a prestigious academic publication dedicated to advancing the field of virology and infectious diseases. Published by WILEY, this journal has established itself as a cornerstone within the scientific community since its inception in 1977, and it will continue to provide cutting-edge research until 2024. With an impressive impact factor that places it in the Q1 quartile for both Infectious Diseases and Virology, the journal ranks 14 out of 344 in Medicine - Infectious Diseases and 6 out of 80 in Immunology and Microbiology - Virology according to Scopus metrics. Its focus encompasses a broad spectrum of topics, including viral pathogenesis, diagnostics, treatment strategies, and epidemiology, making it an essential resource for researchers, clinicians, and students alike. Although not an open-access journal, it provides valuable insights and accessible content for subscribers and libraries. The ongoing commitment to high-quality peer-reviewed articles makes JOURNAL OF MEDICAL VIROLOGY a vital platform for disseminating knowledge and fostering innovation in virology and related fields.

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

VIROLOGIE is a prominent international journal dedicated to advancing the field of virology and infectious diseases, published by John Libbey Eurotext Ltd. Since its inception in 1997, this journal has provided a platform for researchers and professionals to disseminate their findings on various aspects of virology, including the pathogenesis, epidemiology, and treatment of viral infections. Despite its current ranking in Q4 for both Infectious Diseases and Virology categories, the journal remains a valuable resource for emerging research and novel insights. The ISSN for the journal is 1267-8694, and it is based in France. VIROLOGIE is committed to upholding rigorous academic standards and fosters an inclusive scholarly community, making it an essential read for those pursuing knowledge and advancements in the ever-evolving landscape of virology. While the journal does not currently offer open access options, it continues to contribute significantly to the global discourse on viral research through its diverse range of published studies.